Format
Sort by

Send to

Choose Destination

Links from PubMed

Items: 1 to 20 of 129

1.

Successful desensitization to idursulfase in a patient with type II mucopolysaccharidosis (Hunter syndrome).

Serrano CD, Gomez JF.

J Investig Allergol Clin Immunol. 2011;21(7):571-2. No abstract available.

2.

Hunter syndrome: resolution of extensive typical skin lesions after 9 months of enzyme replacement therapy with idursulfase.

Marín LL, Gutiérrez-Solana LG, Fernández AT.

Pediatr Dermatol. 2012 May-Jun;29(3):369-70. doi: 10.1111/j.1525-1470.2011.01418.x. Epub 2011 Oct 13.

PMID:
21995841
3.

Enzyme replacement therapy with idursulfase for mucopolysaccharidosis type II (Hunter syndrome).

da Silva EM, Strufaldi MW, Andriolo RB, Silva LA.

Cochrane Database Syst Rev. 2011 Nov 9;(11):CD008185. doi: 10.1002/14651858.CD008185.pub2. Review. Update in: Cochrane Database Syst Rev. 2014;1:CD008185.

PMID:
22071845
4.

Safety and efficacy of enzyme replacement therapy with idursulfase beta in children aged younger than 6 years with Hunter syndrome.

Sohn YB, Cho SY, Lee J, Kwun Y, Huh R, Jin DK.

Mol Genet Metab. 2015 Feb;114(2):156-60. doi: 10.1016/j.ymgme.2014.08.009. Epub 2014 Aug 30.

PMID:
25219292
5.

Phase I/II clinical trial of enzyme replacement therapy with idursulfase beta in patients with mucopolysaccharidosis II (Hunter syndrome).

Sohn YB, Cho SY, Park SW, Kim SJ, Ko AR, Kwon EK, Han SJ, Jin DK.

Orphanet J Rare Dis. 2013 Mar 18;8:42. doi: 10.1186/1750-1172-8-42.

6.

IgE-mediated anaphylaxis and allergic reactions to idursulfase in patients with Hunter syndrome.

Kim J, Park MR, Kim DS, Lee JO, Maeng SH, Cho SY, Han Y, Ahn K, Jin DK.

Allergy. 2013 Jun;68(6):796-802. doi: 10.1111/all.12155. Epub 2013 Apr 29.

7.

Enzyme replacement therapy with idursulfase for mucopolysaccharidosis type II (Hunter syndrome).

da Silva EM, Strufaldi MW, Andriolo RB, Silva LA.

Cochrane Database Syst Rev. 2014 Jan 8;(1):CD008185. doi: 10.1002/14651858.CD008185.pub3. Review. Update in: Cochrane Database Syst Rev. 2016;2:CD008185.

PMID:
24399699
8.

A phase I/II clinical trial of enzyme replacement therapy in mucopolysaccharidosis II (Hunter syndrome).

Muenzer J, Gucsavas-Calikoglu M, McCandless SE, Schuetz TJ, Kimura A.

Mol Genet Metab. 2007 Mar;90(3):329-37. Epub 2006 Dec 20.

PMID:
17185020
9.

Idursulfase in Hunter syndrome treatment.

Zareba G.

Drugs Today (Barc). 2007 Nov;43(11):759-67. doi: 10.1358/dot.2007.43.11.1157619. Review.

PMID:
18174963
10.

The effect of recombinant human iduronate-2-sulfatase (Idursulfase) on growth in young patients with mucopolysaccharidosis type II.

Żuber Z, Różdżyńska-Świątkowska A, Jurecka A, Tylki-Szymańska A.

PLoS One. 2014 Jan 13;9(1):e85074. doi: 10.1371/journal.pone.0085074. eCollection 2014.

11.
12.

[Early response to idursulfase in a 31-year old male patient with Hunter syndrome].

Pérez-Calvo J, Bergua Sanclemente I, López Moreno MJ, Torralba Cabeza MÁ, Amores Arriaga B.

Rev Clin Esp. 2011 Jul-Aug;211(7):e42-5. doi: 10.1016/j.rce.2011.01.014. Epub 2011 Apr 27. Spanish.

PMID:
21524741
13.

The relationship between anti-idursulfase antibody status and safety and efficacy outcomes in attenuated mucopolysaccharidosis II patients aged 5 years and older treated with intravenous idursulfase.

Barbier AJ, Bielefeld B, Whiteman DA, Natarajan M, Pano A, Amato DA.

Mol Genet Metab. 2013 Nov;110(3):303-10. doi: 10.1016/j.ymgme.2013.08.002. Epub 2013 Aug 9.

14.

A phase II/III clinical study of enzyme replacement therapy with idursulfase in mucopolysaccharidosis II (Hunter syndrome).

Muenzer J, Wraith JE, Beck M, Giugliani R, Harmatz P, Eng CM, Vellodi A, Martin R, Ramaswami U, Gucsavas-Calikoglu M, Vijayaraghavan S, Wendt S, Puga AC, Ulbrich B, Shinawi M, Cleary M, Piper D, Conway AM, Kimura A.

Genet Med. 2006 Aug;8(8):465-73. Erratum in: Genet Med. 2006 Sep;8(9):599. Wendt, Suzanne [corrected to Wendt, Susanne]; Puga, Antonio [corrected to Puga, Ana Cristina]; Conway, Ann Marie [corrected to Conway, Anne Marie].

PMID:
16912578
15.

Treatment of mucopolysaccharidosis type II (Hunter syndrome) with idursulfase: the relevance of clinical trial end points.

Glamuzina E, Fettes E, Bainbridge K, Crook V, Finnegan N, Abulhoul L, Vellodi A.

J Inherit Metab Dis. 2011 Jun;34(3):749-54. doi: 10.1007/s10545-011-9280-1. Epub 2011 Feb 16.

PMID:
21327479
16.

Immunogenicity of idursulfase and clinical outcomes in very young patients (16 months to 7.5 years) with mucopolysaccharidosis II (Hunter syndrome).

Pano A, Barbier AJ, Bielefeld B, Whiteman DA, Amato DA.

Orphanet J Rare Dis. 2015 Apr 24;10:50. doi: 10.1186/s13023-015-0265-2.

17.

A multicenter, open-label study evaluating safety and clinical outcomes in children (1.4-7.5 years) with Hunter syndrome receiving idursulfase enzyme replacement therapy.

Giugliani R, Hwu WL, Tylki-Szymanska A, Whiteman DA, Pano A.

Genet Med. 2014 Jun;16(6):435-41. doi: 10.1038/gim.2013.162. Epub 2013 Nov 7.

18.

Idursulfase for the treatment of mucopolysaccharidosis II.

Clarke LA.

Expert Opin Pharmacother. 2008 Feb;9(2):311-7. doi: 10.1517/14656566.9.2.311 . Review.

PMID:
18201153
19.

Japan Elaprase Treatment (JET) study: idursulfase enzyme replacement therapy in adult patients with attenuated Hunter syndrome (Mucopolysaccharidosis II, MPS II).

Okuyama T, Tanaka A, Suzuki Y, Ida H, Tanaka T, Cox GF, Eto Y, Orii T.

Mol Genet Metab. 2010 Jan;99(1):18-25. doi: 10.1016/j.ymgme.2009.08.006. Epub .

PMID:
19773189
20.

Mucopolysaccharidosis Type II (Hunter Syndrome): clinical picture and treatment.

Beck M.

Curr Pharm Biotechnol. 2011 Jun;12(6):861-6. doi: 1389-2010/11 $58.00+.00. Review.

PMID:
21235446
Items per page

Supplemental Content

Write to the Help Desk